Savara Inc (SVRA) - Total Assets
Based on the latest financial reports, Savara Inc (SVRA) holds total assets worth $192.14 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Savara Inc - Total Assets Trend (2000–2025)
This chart illustrates how Savara Inc's total assets have evolved over time, based on quarterly financial data. Also see SVRA market cap overview for the company's overall valuation and market capitalisation.
Savara Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Savara Inc's total assets of $192.14 Million consist of 95.3% current assets and 4.7% non-current assets. Review SVRA total debt and obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 13.1% |
| Accounts Receivable | $1.25 Million | 0.5% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $11.64 Million | 4.6% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2000–2025)
This chart illustrates how Savara Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See current stock price of Savara Inc for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Savara Inc's current assets represent 95.3% of total assets in 2025, an increase from 10.5% in 2000.
- Cash Position: Cash and equivalents constituted 13.1% of total assets in 2025, up from 10.0% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, a decrease from 89.0% in 2000.
- Asset Diversification: The largest asset category is intangible assets at 4.6% of total assets.
Savara Inc Competitors by Total Assets
Key competitors of Savara Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
Savara Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 10.13 | 11.08 | 16.38 |
| Quick Ratio | 10.13 | 11.08 | 16.38 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $160.72 Million | $137.36 Million | $163.92 Million |
Savara Inc - Advanced Valuation Insights
This section examines the relationship between Savara Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.67 |
| Latest Market Cap to Assets Ratio | 4.26 |
| Asset Growth Rate (YoY) | 19.1% |
| Total Assets | $253.44 Million |
| Market Capitalization | $1.08 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Savara Inc's assets at a significant premium (4.26x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Savara Inc's assets grew by 19.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Savara Inc (2000–2025)
The table below shows the annual total assets of Savara Inc from 2000 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $253.44 Million | +19.05% |
| 2024-12-31 | $212.88 Million | +19.89% |
| 2023-12-31 | $177.56 Million | +27.03% |
| 2022-12-31 | $139.78 Million | -20.85% |
| 2021-12-31 | $176.60 Million | +80.67% |
| 2020-12-31 | $97.75 Million | -28.24% |
| 2019-12-31 | $136.20 Million | -10.56% |
| 2018-12-31 | $152.29 Million | -4.60% |
| 2017-12-31 | $159.63 Million | +451.70% |
| 2016-12-31 | $28.93 Million | -46.63% |
| 2015-12-31 | $54.22 Million | -23.10% |
| 2014-12-31 | $70.50 Million | +27.60% |
| 2013-12-31 | $55.25 Million | +17.62% |
| 2012-12-31 | $46.97 Million | -24.06% |
| 2011-12-31 | $61.86 Million | +117.14% |
| 2010-12-31 | $28.49 Million | +215.57% |
| 2009-12-31 | $9.03 Million | -15.71% |
| 2008-12-31 | $10.71 Million | -69.00% |
| 2007-12-31 | $34.54 Million | -34.58% |
| 2006-12-31 | $52.80 Million | +123.52% |
| 2005-12-31 | $23.62 Million | +73.58% |
| 2004-12-31 | $13.61 Million | +217.71% |
| 2003-12-31 | $4.28 Million | +3186.17% |
| 2002-12-31 | $130.34K | -53.11% |
| 2001-12-31 | $278.01K | -98.13% |
| 2000-12-31 | $14.88 Million | -- |
About Savara Inc
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Yardley, P… Read more